| Primary | Incidence of Hypophosphatemia (S-phosphate Level <2 mg/dL) | Safety The incidence of hypophosphatemia (defined as s-phosphate <2 mg/dL) at any time from baseline up to day 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Count of Participants | | Participants | | Baseline to day 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| | | Title | Denominators | Categories |
|---|
| | |
| | Group IDs | Group Description | Statistical Method | Statistical Comment | P-Value | P-Value Comment | Parameter Type | Parameter Value | Dispersion Type | Dispersion Value | Confidence Interval Sides | Confidence Interval % | CI Lower Limit | CI Upper Limit | CI Lower Limit Comment | CI Upper Limit Comment | Estimate Comment | Tested Non-Inferiority | Non-Inferiority Type | Non-Inferiority Comment | Other Analysis Description |
|---|
| Power: The power was set to 80%. Assuming incidences of 15% for iron isomaltoside/ferric derisomaltose and 40% for ferric carboxymaltose, 49 subjects in each treatment group were required to detect a difference between the treatment groups. The significance level was set to 5%. | Cochran-Mantel-Haenszel | | <0.0001 | | Risk Difference (RD) | -67.0 | | | 2-Sided | 95 | -77.4 | -51.5 | | | Iron isomaltoside/ferric derisomaltose was compared to ferric carboxymaltose by estimation of the risk difference and the associated 95% CI, adjusting for strata (underlying disease and screening s-phosphate) using the Cochran-Mantel-Haenszel method. | | |
|
| Secondary | Time With Hypophosphatemia ( S-phosphate Level <2.0 mg/dL) | Safety Time with hypophosphatemia (i.e. time with s-phosphate level < 2.0 mg/dL) from baseline up to day 35. The time with hypophosphatemia was calculated as the actual number of days from the first day where s-phosphate was <2 mg/dL until the first day when s-phosphate was ≥2 mg/dL. If the subject did not reach s-phosphate ≥2 mg/dL, the subject was regarded as censored on day 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Median | 95% Confidence Interval | days | | Baseline to day 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Proportion of Subjects With Hypophosphatemia on Day 35 ( S-phosphate Level <2.0 mg/dL) | Safety Evaluate the proportion of subjects with hypophosphatemia (s-phosphate level <2.0 mg/dL) on day 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Count of Participants | | Participants | | Baseline to day 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Absolute [∆] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35 | Safety Absolute [∆] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Relative [%] Changes in S-phosphate From Baseline to Day 1, 7, 8, 14, 21, and 35 | Safety Relative [%] changes in s-phosphate from baseline to day 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | Percentage change from baseline | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron Isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change From Baseline in Fractional Phosphate Urinary Excretion | Safety Change in absolute fractional phosphate urinary excretion from baseline to days 1, 7, 8, 14, 21, and 35. Fractional excretion of phosphate (FEPi) is calculated as ([phosphate in urine X creatinine in serum]/[phosphate in serum X creatinine in urine]) X 100, and the unit is %. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | percentage excreted | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) From Baseline to Day 1, 7, 8, 14, 21, and 35 | Safety Change in concentration of (Intact) Fibroblast Growth Factor 23 (iFGF23) from baseline to day 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | pg/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in C-terminal Fibroblast Growth Factor 23 (cFGF23) from baseline to days 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | RU/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Vitamin 25-Hydroxyvitamin D (Vitamin D 25) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in vitamin 25-Hydroxyvitamin D (vitamin D 25) from baseline to days 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | ng/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in 1,25-Dihydroxyvitamin D (Vitamin D 1.25) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in 1,25-Dihydroxyvitamin D (vitamin D 1.25) from baseline to days 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | pg/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in 24,25-Dihydroxyvitamin D (Vitamin D 24.25) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in 24,25-Dihydroxyvitamin D (vitamin D 24.25) from baseline to days 1, 7, 8, 14, 21, and 35 | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | ng/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Intact Parathyroid Hormone (PTH) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in intact Parathyroid hormone (PTH) from baseline to days 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Mean | Standard Deviation | pg/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Ionized Calcium From Baseline to Days 1, 7, 8, 14, 21, and 35 | Safety Change in ionized calcium from baseline to days 1, 7, 8, 14, 21, and 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product | Posted | | Mean | Standard Deviation | mg/dL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions | Safety For this endpoint, the number of participants with serious or severe hypersensitivity reactions were evaluated. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Count of Participants | | Participants | | Baseline to day 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Hemoglobin (Hb) Per Gram Iron From Baseline to Days 1, 7, 8, 14, 21, and 35 | Efficacy Change in hemoglobin (Hb) per gram iron from baseline to days 1, 7, 8, 14, 21, and 35. | Intention-To-Treat (ITT) analysis set: included all randomised subjects. | Posted | | Mean | Standard Deviation | g/dL per g of iron | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in S-ferritin From Baseline to Days 1, 7, 8, 14, 21, and 35 | Efficacy Change in s-ferritin from baseline to days 1, 7, 8, 14, 21, and 35. | Intention-To-Treat (ITT) analysis set: included all randomised subjects. | Posted | | Mean | Standard Deviation | ng/mL | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Secondary | Change in Transferrin Saturation (TSAT) From Baseline to Days 1, 7, 8, 14, 21, and 35 | Efficacy Change in Transferrin Saturation (TSAT) from baseline to days 1, 7, 8, 14, 21, and 35. TSAT is the value of serum iron divided by the total iron-binding capacity and the unit is %, which referrers to % of iron-binding sites of transferrin being occupied by iron. | Intention-To-Treat (ITT) analysis set: included all randomised subjects. | Posted | | Mean | Standard Deviation | percentage of saturation | | Baseline, days 1, 7, 8, 14, 21, and 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |
| Post-Hoc | Incidence of S-phosphate Level ≤1.0 mg/dL at Any Time From Baseline to Day 35 | Safety Incidence of hypophosphatemia (defined as s-phosphate level ≤1 mg/dL) at any time from baseline up to day 35. | Safety analysis set: included all subjects who received at least one dose of the investigational product. | Posted | | Count of Participants | | Participants | | Baseline to day 35 | | | | ID | Title | Description |
|---|
| OG000 | Iron Isomaltoside/Ferric Derisomaltose | Iron isomaltoside/ferric derisomaltose, administered IV | | OG001 | Ferric Carboxymaltose | Ferric carboxymaltose, administered IV |
| |